BioCentury
ARTICLE | Company News

Emergent BioSolutions, MorphoSys deal

September 1, 2014 7:00 AM UTC

MorphoSys partnered with Emergent to develop and commercialize ES414. Emergent developed the bispecific ADAPTIR antibody targeting prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) and CD3. The compound -- to be renamed MOR209/ES414 -- is in preclinical testing to treat prostate cancer. The companies will jointly develop the compound, with MorphoSys bearing 64% and Emergent 36% of the total costs. MorphoSys will gain worldwide commercialization rights, excluding the U.S. and Canada, where Emergent will retain rights. ...